Cartesian Therapeutics. has been granted a patent for chimeric antigen receptors (CARs) targeting B-Cell Maturation Antigen (BCMA). These CARs enhance T cell binding and efficacy against BCMA-expressing cancer cells, detailing specific amino acid sequences for the antigen-binding domains. GlobalData’s report on Cartesian Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cartesian Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Cartesian Therapeutics's grant share as of June 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric antigen receptors targeting b-cell maturation antigen
The granted patent US11999773B2 outlines a novel protein that features an antigen-binding portion specifically targeting the B-Cell Maturation Antigen (BCMA). The claims detail the composition of this protein, which includes various complementarity determining regions (CDRs) from both heavy and light chains. Specifically, the heavy chain comprises three CDRs (CDRH1, CDRH2, and CDRH3) with specified sequences (SEQ ID NOs: 1-9), while the light chain includes three additional CDRs (CDRL1, CDRL2, and CDRL3) with designated sequences (SEQ ID NOs: 11-18). The claims allow for variations in the specific sequences of these CDRs, providing flexibility in the design of the protein.
Further claims refine the protein's characteristics by specifying particular sequences for each CDR, including combinations that enhance its binding efficacy. For instance, claims 2 through 9 detail specific sequence selections for CDRH1, CDRH2, CDRH3, CDRL2, and CDRL3, allowing for a tailored approach to the protein's design. Additionally, claim 10 introduces the possibility of the protein being a bispecific antibody, which could have implications for therapeutic applications targeting BCMA. This patent thus presents a structured approach to developing proteins with potential uses in medical treatments, particularly in conditions related to B-cell activity.
To know more about GlobalData’s detailed insights on Cartesian Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
